Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Under Medicare: Shift From Medicaid Means $200 Mil. Less Rebates

Executive Summary

The transfer of "dual eligible" Zyprexa patients from Medicaid to the new Medicare drug benefit means that Lilly's rebate payments to states will be reduced by about $200 mil. per year

You may also be interested in...



Antipsychotic Medicare Prices Are 15%-30% Off AWP; Abilify Is Outlier

Bristol-Myers Squibb's antipsychotic Abilify (aripiprazole) is being offered at less than half of list price under the National Community Pharmacy Association's Medicare-endorsed discount card brands

Antipsychotic Medicare Prices Are 15%-30% Off AWP; Abilify Is Outlier

Bristol-Myers Squibb's antipsychotic Abilify (aripiprazole) is being offered at less than half of list price under the National Community Pharmacy Association's Medicare-endorsed discount card brands

Neurontin Off-Label Use Needs Prior Authorization Under Fla. Medicaid Plan

Prior authorization for off-label use of Pfizer's Neurontin would save the Florida Medicaid program $7 mil., the FY 2004-2005 budget proposal states

Related Content

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel